Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. [electronic resource]
Producer: 20090605Description: 2436-42 p. digitalISSN:- 1527-7755
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Analgesics, Non-Narcotic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Neoplasms -- drug therapy
- Bone and Bones -- drug effects
- Docetaxel
- Drug Resistance, Neoplasm
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Organometallic Compounds -- administration & dosage
- Organophosphorus Compounds -- administration & dosage
- Prostate-Specific Antigen -- blood
- Prostatic Neoplasms -- drug therapy
- Radiopharmaceuticals -- administration & dosage
- Taxoids -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.